We are a diverse group – molecular biologists, MDs, PharmDs, tumor immunologists, stem cell biologists and computational scientists – at all career stages. We architect strategies to dissect and manipulate immune cell identity.


Filipe Pereira, PhD

Group Leader

Cristiana Pires, PharmD PhD

Postdoctoral Fellow

Olga Zimmermannova, MD PhD

Cancerfonden Postdoctoral Fellow

Marta Laranjeiro Pinto, PhD

Postdoctoral Fellow

Hreinn Benónísson, PhD

Postdoctoral Fellow

Ilia Kurochkin, PhD

Computational Postdoctoral Fellow

Camila Vazquez Echegaray, PhD

Postdoctoral Fellow

Lavínia Romera, PhD

Postdoctoral Fellow

Fábio Fiúza Rosa

PhD Student

Rita Alves

PhD Student

Inês Caiado

PhD Student

Nejc Arh

PhD Student

Ervin Ascic


Abigail Altman

Project Assistant

Evelyn Halitzki

MSc Student

Alexander Kuzmin

MSc Student

Diogo Cabral

MSc Student

Nina Lipjankic

MSc Student

Robin Scheuplein

MSc Student

Susana Pedreiro

Technician/Lab Manager


Luis Galán Palma

Former Erasmus Student

Currently PhD Student at Anna Bigas Lab. Hospital del Mar Institute, Barcelona, Spain

Ariane Tenreiro

Former MSc Student

Currently Research Fellow at David Breault Lab. Harvard Stem Cell Institute, Boston, US

Svandís Sæmundsdóttir

Former Computational MSc Student

Currently Associate Consultant at Cerner Corporation, Malmö, Sweden

Sara Llorente Armijo

Former MSc student

Currently PhD Student at MRC Clinical Sciences Center, Imperial College, London, UK

Andreia Gomes

Former PhD Student

Currently Sales Representative at Enzymatic SA, Lisbon, Portugal.

Monika Malz

Former Kapital Ludzki Student

Currently PhD Student at DZNE, Bonn, Germany

Rigveda Bhave

Former MSc Student

Currently PhD Student at Vrije University of Brussels, Belgium

Kritika Shaiv

Former MSc Student

Currently PhD Student at National Tsing Hua University, Hsinchu City, Taiwan

Raquel Marques

Former Student

Currently PhD Student at ICVS School of Medicine, Minho University, Braga, Portugal

Catarina Silva

Former MSc Student

Currently PhD Student at i3S, Porto, Portugal

Raquel Santos

Former MSc Student

Currently PhD Student at CNC, Coimbra, Portugal

Frederick Korbel

Former BSc Student

Currently MSc Student at Charité - Berlin University, Berlin, Germany

Cláudia Azenha

Former MSc Student

Currently Researcher at Biocant Park, Cantanhede, Portugal

Jakob Haider

Former BSc Student

Currently MSc Student at Lund University, Lund, Sweden

Jennyfer Pastor Gómez

Former MSc Student

Currently Intern at SYNLAB Analytics & Services (A&S)

Diego Cabrera

Former MSc Student

Tasnim Zahan

Former MSc Student


Caetano Reis e Sousa

Francis Crick Institute

Dendritic Cells. London, UK

Ewa Sitnicka

Lund University

NK Cell Biology. Lund, Sweden

Stephanie Hugues

University of Geneva

Tumor Immunology. Geneva, Switzerland

Jenny Hansson

Lund University

Proteomics. Lund, Sweden

Sonja Buschow

Erasmus MC

Immunopeptidomics. Rotterdam, Netherlands

Francesca Aguilo

Umeå University

Epigenetics. Umeå, Sweden

Johan Bengzon

Skåne University Hospital

Clinical. Neurosurgery. Lund, Sweden

Dung-Fang Lee

MD Anderson Cancer Center

Kinases and Phosphatases. Texas, U.S.

Kenichi Miharada

Lund University

Cancer Cell Reprogramming. Lund, Sweden

Raquel Almeida


Cancer Stem Cells. Porto, Portugal

Kateri Moore

Mount Sinai

Hematopoietic Stem Cells. New York, U.S.

Stefan Karlsson

Lund University

Gene Therapy. Lund, Sweden

Kees-Jan Pronk

Skåne University Hospital

Clinical. Hematology. Lund, Sweden

Göran B Jönsson

Lund University

Melanoma. Lund, Sweden

Malin Lindstedt

Lund University

Head and Neck Cancer. Lund, Sweden

Cristian Bellodi

Lund University

Epitranscriptomics. Lund, Sweden

Marella de Brujin

Weatherall Institute of Molecular Medicine

Developmental Hematopoiesis. Oxford, UK

Transgenic Core Facility

University of Copenhagen

Transgenic Mouse Model Generation. Copenhagen, Denmark

Drug Discovery and Development Platform


Small Molecule Screening. Stockholm, Sweden


Asgard Therapeutics

An important hallmark of cancer is the ability to evade the immune system. Asgard Therapeutics has the goal to establish dendritic cell reprogramming as an entirely new approach to unleash the immune system against cancer.

Blood Reprogramming Technologies

Blood Reprogramming Technologies is a biotechnology start-up focused on the use of direct cell reprogramming to generate innovative solutions for hematopoietic stem cell transplantation and blood regeneration.